Clinical trial · Observational
Magnesium and Dexmedetomidine in Pheochromocytoma
Magnesium and Dexmedetomidine Combination Reduces Sodium Nitroprusside Requirement in Laparoscopic Pheochromocytoma
NCT05102058CI-TRIAL-00054791completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Anesthesia management of pheochromocytoma excision surgery is associated with severe hemodynamic fluctuations.The objective of this study was to compare the hypertensive episodes requiring sodium nitroprusside administration between the group treated with magnesium-dexmedetomidine and conventional group in pheochromocytoma.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Hemodynamic Instability | — | UNRESOLVED | — |
| Phaeochromocytoma Crisis | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Magnesium-Dexmedetomidine | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- Conventional group (GC)
- description
- Not receive perioperative additional medication.
- label
- Magnesium-dexmedetomidine therapy group (GMD)
- description
- Received oral 300 mg magnesium one week before surgery and magnesium-dexmedetomidine combination perioperatively.
- interventionNames
- Drug: Magnesium-Dexmedetomidine
Primary outcomes (1)
- measure
- Sodium nitroprusside (SNP) requirement
- timeFrame
- intraoperative period
- description
- intraoperative hypertensive episodes requiring SNP therapy
Secondary outcomes (1)
- measure
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: * American Society of Anesthesiologists classification (ASA) 1-3 * high urinary catecholamine or metabolites * tumor sizes \< 5 cm * body mass index (BMI) \<35 kg/m2 Exclusion Criteria: * open surgery * bilateral masses * tumor larger than 5 cm * incomplete data
References
Publications (0)
Data not yet available
No reference posted for this study.